Patent application number | Description | Published |
20090291891 | VEGF variant that lacks VEGFR-1 binding activity and its use in promotion of re-endothelization and prevention of in-stent restenosis | 11-26-2009 |
20100119515 | PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. | 05-13-2010 |
20100247516 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 09-30-2010 |
20100317721 | Compositions and Methods for Treating Tumors, Fibrosis, and Pulmonary Alveolar Proteinosis - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 12-16-2010 |
20120101029 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 04-26-2012 |
20120165398 | PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. | 06-28-2012 |
20120202206 | PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. | 08-09-2012 |
20130022617 | COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 01-24-2013 |
20130287726 | COMPOSITIONS COMPRISING SEMAPHORINS FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND METHODS OF SELECTION THEREOF - A method of selecting a semaphorin for treating cancer in a subject is disclosed. The method comprises determining an expression of a semaphorin receptor on tumor cells of a tumor sample of the subject wherein an amount of the semaphorin receptor is indicative of the semaphorin suitable for treating the cancer in the subject. Methods of treating angiogenesis, kits for treating cancer and pharmaceutical compositions comprising semaphorins are also disclosed. | 10-31-2013 |
20130330349 | HIGH AFFINITY MOLECULES CAPABLE OF BINDING A TYPE A PLEXIN RECEPTOR AND USES OF SAME - A high affinity molecule is provided. The high affinity molecule comprises a binding domain which binds a type-A plexin receptor, wherein said binding domain inhibits proliferative signals through said type-A plexin receptor but does not interfere with binding of a neuropilin or semaphorin 6A to said type-A plexin receptor. | 12-12-2013 |
20140302499 | PHARMACEUTICAL COMPOSITIONS AND METHODS USEFUL FOR MODULATING ANGIOGENESIS, INHIBITING METASTASIS AND TUMOR FIBROSIS, AND ASSESSING THE MALIGNANCY OF COLON CANCER TUMORS - Methods and compositions suitable for modulating angiogenesis in a mammalian tissue are provided. Further provided are methods suitable for inhibiting metastasis and fibrosis in a mammalian tissue and for assessing the malignancy of colon cancer tumors. | 10-09-2014 |
20150044199 | COMPOSITIONS AND METHODS FOR TREATING TUMORS, FIBROSIS, AND PULMONARY ALVEOLAR PROTEINOSIS - The present disclosure provides pharmaceutical compositions and methods useful for modulating angiogenesis and for inhibiting metastasis, tumors, pulmonary alveolar proteinosis, and fibrosis in a mammalian tissue. Pharmaceutical compositions and methods include inhibitors of LOXL2 expression and activity, such as shRNA targeting LOXL2. | 02-12-2015 |
Patent application number | Description | Published |
20080319287 | Implantable Power Sources and Sensors - A protein is provided, including a glucose binding site, cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP). The protein is configured such that binding of glucose to the glucose binding site causes a reduction in a distance between the CFP and the YFP. Substance monitoring apparatus ( | 12-25-2008 |
20090061524 | Enzyme-Channeling Based Electrochemical Biosensors - Low-cost, non-toxic and fast immunoassay systems (immunosensors) and uses thereof as analytical and diagnostic tools for detecting an immune response in a subject are disclosed. The systems and methods disclosed are based on recording an electrochemical signal which is generated proportionally to an enzymatic cascade reaction (enzyme-channeling) upon detecting an analyte, and therefore can be used to determine the titer level of an antibody analyte in a liquid sample such as artificial media, serum or blood both qualitatively and quantitatively, in a one-step and separation free immunoassay. Systems and methods based on recording an electrochemical signal which is generated proportionally to an enzymatic cascade reaction (enzyme-channeling) upon detecting an analyte, which utilize a non-toxic secondary substrate such as acetaminophen are also disclosed. | 03-05-2009 |
20090232740 | Methods of detecting cancer cells and use of same for diagnosing and monitoring treatment of the disease - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with said substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of said electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy. | 09-17-2009 |
20100047311 | PROTECTING ALGAE FROM BODY FLUIDS - Apparatus ( | 02-25-2010 |
20110165219 | OPTIMIZATION OF ALGINATE ENCAPSULATION OF ISLETS FOR TRANSPLANTATION - Apparatus is provided, including a plurality of islets, and a hydrogel configured to macroencapsulate the plurality of islets. The hydrogel is implantable in a subcapsular space ( | 07-07-2011 |
20110251471 | IMPLANTABLE POWER SOURCES AND SENSORS - A protein is provided, including a glucose binding site, cyan fluorescent protein (CFP), and yellow fluorescent protein (YFP). The protein is configured such that binding of glucose to the glucose binding site causes a reduction in a distance between the CFP and the YFP. Substance monitoring apparatus ( | 10-13-2011 |
20110300191 | MULTIPLE-LAYER IMMUNE BARRIER FOR DONOR CELLS - A system is provided, including a plurality of donor cells and a first alginate structure that encapsulates the plurality of donor cells. The first alginate structure has a guluronic acid concentration of between 64% and 74%. The system additionally includes a second alginate structure that surrounds the first alginate structure, the second alginate structure having a mannuronic acid concentration of between 52% and 60%. A selectively-permeable membrane is coupled at least in part to the second alginate structure. Other embodiments are also described. | 12-08-2011 |
20120288877 | ELECTROCHEMICAL METHODS OF DETECTING COLON CANCER CELLS AND USE OF SAME FOR DIAGNOSING AND MONITORING TREATMENT OF THE DISEASE - A method of detecting cancer cells is disclosed. The method comprises (a) contacting the cell with a substrate for an enzyme under conditions wherein the enzyme catalyzes a reaction of the cell with the substrate, so as to generate a product capable of producing an electrical signal; and (b) measuring a level of the electrical signal, wherein a difference in a level of the electrical signal compared to a predetermined threshold is indicative of a cancer cell. The method may be adapted for diagnosis, monitoring a cancer therapy, identifying agents capable of treating cancer and individually optimizing a cancer therapy. | 11-15-2012 |